Eli Lilly continues dealmaking roll with $1bn AlzeCure agreement - Pharmaceutical Technology

If AlzeCure-developed ACD680 reached the market, it would deepen Eli Lilly’s Alzheimer’s legacy past anti-amyloid-beta therapy, Kisunla. If ACD680 were to reach the market, it would deepen Lilly’s Alzheimer’s legacy past anti-amyloid-beta therapy, Kisunla. Eli Lilly is looking to deepen its legacy in the Alzheimer’s space through a licensing deal with biotech, AlzeCure. Credit: Only_NewPhoto / Shutterstock.com. Eli Lilly has inked a licensing deal worth up to $1bn with Swedish Alzheimer’s-focused biotech, AlzeCure – marking a continuation of the pharma giant’s 2026 dealmaking spree. Lilly will secure the rights to AlzeCure’s therapeutic candidate, ACD680, in exchange for $10m upfront, more…

Source: Pharmaceutical Technology